1
|
Serra-Compte A, González S, Arnaldos M, Berlendis S, Courtois S, Loret JF, Schlosser O, Yáñez AM, Soria-Soria E, Fittipaldi M, Saucedo G, Pinar-Méndez A, Paraira M, Galofré B, Lema JM, Balboa S, Mauricio-Iglesias M, Bosch A, Pintó RM, Bertrand I, Gantzer C, Montero C, Litrico X. Elimination of SARS-CoV-2 along wastewater and sludge treatment processes. Water Res 2021; 202:117435. [PMID: 34330027 PMCID: PMC8280618 DOI: 10.1016/j.watres.2021.117435] [Citation(s) in RCA: 34] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/26/2021] [Revised: 06/26/2021] [Accepted: 07/09/2021] [Indexed: 05/06/2023]
Abstract
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is shed in the feces of infected people. As a consequence, genomic RNA of the virus can be detected in wastewater. Although the presence of viral RNA does not inform on the infectivity of the virus, this presence of genetic material raised the question of the effectiveness of treatment processes in reducing the virus in wastewater and sludge. In this work, treatment lines of 16 wastewater treatment plants were monitored to evaluate the removal of SARS-CoV-2 RNA in raw, processed waters and sludge, from March to May 2020. Viral RNA copies were enumerated using reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) in 5 different laboratories. These laboratories participated in proficiency testing scheme and their results demonstrated the reliability and comparability of the results obtained for each one. SARS-CoV-2 RNA was found in 50.5% of the 101 influent wastewater samples characterized. Positive results were detected more frequently in those regions with a COVID-19 incidence higher than 100 cases per 100,000 inhabitants. Wastewater treatment plants (WWTPs) significantly reduced the occurrence of virus RNA along the water treatment lines. Secondary treatment effluents showed an occurrence of SARS-CoV-2 RNA in 23.3% of the samples and no positive results were found after MBR and chlorination. Non-treated sludge (from primary and secondary treatments) presented a higher occurrence of SARS-CoV-2 RNA than the corresponding water samples, demonstrating the affinity of virus particles for solids. Furthermore, SARS-CoV-2 RNA was detected in treated sludge after thickening and anaerobic digestion, whereas viral RNA was completely eliminated from sludge only when thermal hydrolysis was applied. Finally, co-analysis of SARS-CoV-2 and F-specific RNA bacteriophages was done in the same water and sludge samples in order to investigate the potential use of these bacteriophages as indicators of SARS-CoV-2 fate and reduction along the wastewater treatment.
Collapse
Affiliation(s)
| | - Susana González
- Cetaqua, Water Technology Centre, Cornellà de Llobregat, Spain
| | - Marina Arnaldos
- Cetaqua, Water Technology Centre, Cornellà de Llobregat, Spain
| | - Sabrina Berlendis
- Suez, Centre International de Recherche sur l'Eau et l'Environnement (CIRSEE), Le Pecq, France
| | - Sophie Courtois
- Suez, Centre International de Recherche sur l'Eau et l'Environnement (CIRSEE), Le Pecq, France
| | - Jean Francois Loret
- Suez, Centre International de Recherche sur l'Eau et l'Environnement (CIRSEE), Le Pecq, France
| | - Olivier Schlosser
- Suez, Centre International de Recherche sur l'Eau et l'Environnement (CIRSEE), Le Pecq, France
| | | | | | | | | | | | | | | | - Juan M Lema
- CRETUS Institute, Universidade de Santiago de Compostela, Santiago de Compostela, Spain
| | - Sabela Balboa
- CRETUS Institute, Universidade de Santiago de Compostela, Santiago de Compostela, Spain
| | | | | | | | | | | | - Carlos Montero
- Cetaqua, Water Technology Centre, Cornellà de Llobregat, Spain
| | | |
Collapse
|
2
|
Kim S, Klugman J, Norell S, Kenefake A, Komos L, Jain D, Corcoran M, Montero C, Kreppel A, Sales J, Porto I, Wang J, Hsu LL, Erwin K. Improving VTE prophylaxis adherence among hospitalized adolescents using Human-Centered Design. Journal of Patient Safety and Risk Management 2021. [DOI: 10.1177/25160435211036784] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Background/problem statement Venous thromboembolism (VTE) is the leading cause of preventable hospital mortality in the United States; however, compliance with VTE prophylaxis is poor. Most materials for education about VTE prophylaxis are oriented toward adults rather than adolescents, for whom VTE risks are lower and prophylaxis indications differ. We hypothesized that educational materials for adolescents could improve compliance with VTE prophylaxis, reduce nurse burden for initiating and maintaining VTE prevention practices, and reduce practice variation by standardizing the conversation between clinicians and patients. Methods A multidisciplinary team including physicians, nurses, quality experts, communication designers, service designers, and medical students applied a human-centered design (HCD) process to define, iteratively prototype, and test education tools for nurses assigned to adolescents. We piloted a suite of six educational tools for adolescent VTE prophylaxis to fit into the existing hospital workflow. Results An in-room poster was selected after 85% of nurses responded favorably to this intervention. Adolescent adherence with Intermittent Pneumatic Compression Device increased from 69% to 79%, attaining the benchmark goal of 78%. Staff reported greater confidence in educating adolescent patients after the intervention: 62% of nurses and 72% of residents. Conclusion An HCD process helped nurses improve VTE prophylaxis for adolescents with an in-room poster and messaging strategy. Engaging staff in the design increased receptivity and adoption. The piloted materials also helped to create an environment of shared priority among the clinicians.
Collapse
Affiliation(s)
- Soobin Kim
- Department of Pediatrics, University of Illinois at Chicago, Chicago, Illinois, USA
| | - Jessie Klugman
- Department of Pediatrics, University of Illinois at Chicago, Chicago, Illinois, USA
| | - Sarah Norell
- Institute for Healthcare Delivery Design, University of Illinois at Chicago, Chicago, Illinois, USA
| | - Alexandra Kenefake
- Department of Pediatrics, University of Illinois at Chicago, Chicago, Illinois, USA
| | - Laurel Komos
- Institute for Healthcare Delivery Design, University of Illinois at Chicago, Chicago, Illinois, USA
| | - Divya Jain
- Institute for Healthcare Delivery Design, University of Illinois at Chicago, Chicago, Illinois, USA
| | - Moire Corcoran
- Institute for Healthcare Delivery Design, University of Illinois at Chicago, Chicago, Illinois, USA
| | - Carlos Montero
- Department of Pediatrics, University of Illinois at Chicago, Chicago, Illinois, USA
| | - Andrew Kreppel
- Department of Pediatrics, University of Illinois at Chicago, Chicago, Illinois, USA
| | - Jocelyn Sales
- Department of Pediatrics, University of Illinois at Chicago, Chicago, Illinois, USA
| | - Isabel Porto
- Department of Pediatrics, University of Illinois at Chicago, Chicago, Illinois, USA
| | - Jenny Wang
- Department of Pediatrics, University of Illinois at Chicago, Chicago, Illinois, USA
| | - Lewis L. Hsu
- Department of Pediatrics, University of Illinois at Chicago, Chicago, Illinois, USA
| | - Kim Erwin
- Institute for Healthcare Delivery Design, University of Illinois at Chicago, Chicago, Illinois, USA
| |
Collapse
|
3
|
Pérez-Pérez D, Sordo-Puga Y, Rodríguez-Moltó MP, Sardina T, Santana E, Montero C, Ancizar J, Cabrera Y, Tuero Á, Naranjo P, Sosa-Testé I, Fernandez F, Valdés R, Duarte CA, Suárez-Pedroso M. E2-CD154 vaccine candidate is safe and immunogenic in pregnant sows, and the maternal derived neutralizing antibodies protect piglets from classical swine fever virus challenge. Vet Microbiol 2021; 260:109153. [PMID: 34271304 DOI: 10.1016/j.vetmic.2021.109153] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2021] [Accepted: 06/13/2021] [Indexed: 11/19/2022]
Abstract
E2-CD154 subunit vaccine candidate is safe and protects swine from Classical Swine Fever (CSF). However, its safety and immunogenicity in pregnant sows, and the capacity of maternal derived neutralizing antibodies (MDNA) to protect the offspring is yet to be demonstrated. The aim of this study was to evaluate the safety and immunogenicity of E2-CD154 in pregnant sows, and the capacity of MDNA to protect the offspring. Seventeen pregnant sows were vaccinated twice with E2-CD154 in either the first or the second third of pregnancy. Pregnancy and litter parameters were compared with a control group of non-vaccinated sows. Neutralizing antibodies (NAb) were monitored. The time course of MDNA was assessed in a group of six piglets born to an E2-CD154 immunized sow, and the animals were challenged with CSFV at day 63 after birth. No local or systemic adverse effects were found. Neither abortions, nor congenital malformations, nor stillbirths were observed. All sows develop high NAb titers after the first immunization. Piglets born to an E2-CD154 vaccinated sow still showed MDNA titers of 1:100 at day 63 after birth. Five animals were negative for virus isolation after challenge, and showed neither signs of CSF, nor macroscopic lesions in the organs. The other piglet was positive for CSFV isolation, and macroscopic lesions were observed in the spleen, although no clinical signs of CSF other than fever were detected. E2-CD154 vaccine candidate was safe and immunogenic in pregnant sows, and the passive immunity transmitted to the offspring was still protective by day 63 after birth.
Collapse
Affiliation(s)
- Danny Pérez-Pérez
- Departamento de Biotecnología Animal, Centro de Ingeniería Genética y Biotecnología (CIGB), Ave 31 e/158 y 190, Apdo 6162, Cubanacán, Playa, La Habana, 10600, Cuba.
| | - Yusmel Sordo-Puga
- Departamento de Biotecnología Animal, Centro de Ingeniería Genética y Biotecnología (CIGB), Ave 31 e/158 y 190, Apdo 6162, Cubanacán, Playa, La Habana, 10600, Cuba
| | - María Pilar Rodríguez-Moltó
- Departamento de Biotecnología Animal, Centro de Ingeniería Genética y Biotecnología (CIGB), Ave 31 e/158 y 190, Apdo 6162, Cubanacán, Playa, La Habana, 10600, Cuba
| | - Talía Sardina
- Departamento de Biotecnología Animal, Centro de Ingeniería Genética y Biotecnología (CIGB), Ave 31 e/158 y 190, Apdo 6162, Cubanacán, Playa, La Habana, 10600, Cuba
| | - Elaine Santana
- Departamento de Biotecnología Animal, Centro de Ingeniería Genética y Biotecnología (CIGB), Ave 31 e/158 y 190, Apdo 6162, Cubanacán, Playa, La Habana, 10600, Cuba
| | - Carlos Montero
- Departamento de Biotecnología Animal, Centro de Ingeniería Genética y Biotecnología (CIGB), Ave 31 e/158 y 190, Apdo 6162, Cubanacán, Playa, La Habana, 10600, Cuba
| | - Julio Ancizar
- Instituto de Investigaciones Porcinas, Guatao, km 1(½), Punta Brava, La Lisa, La Habana, 19200, Cuba
| | - Yaneris Cabrera
- Instituto de Investigaciones Porcinas, Guatao, km 1(½), Punta Brava, La Lisa, La Habana, 19200, Cuba
| | - Ángela Tuero
- Dirección de Estudios Clínicos, Centro de Ingeniería Genética y Biotecnología, La Habana, Cuba
| | | | - Iliana Sosa-Testé
- Centro de Toxicología Experimental (CETEX), Centro para la Producción de Animales de Laboratorio (CENPALAB), Mayabeque, Cuba
| | - Fé Fernandez
- Centro de Toxicología Experimental (CETEX), Centro para la Producción de Animales de Laboratorio (CENPALAB), Mayabeque, Cuba
| | - Rodolfo Valdés
- Departamento de Producción de Anticuerpos Monoclonales, Centro de Ingeniería Genética y Biotecnología, La Habana, Cuba
| | - Carlos A Duarte
- Departamento de Biotecnología Animal, Centro de Ingeniería Genética y Biotecnología (CIGB), Ave 31 e/158 y 190, Apdo 6162, Cubanacán, Playa, La Habana, 10600, Cuba
| | - Marisela Suárez-Pedroso
- Departamento de Biotecnología Animal, Centro de Ingeniería Genética y Biotecnología (CIGB), Ave 31 e/158 y 190, Apdo 6162, Cubanacán, Playa, La Habana, 10600, Cuba
| |
Collapse
|
4
|
Allen B, Christenson R, Cohen S, Nowak R, Wilkerson G, Mumma B, Madsen T, McCord J, Huis In 'T Veld M, Massoomi M, Stopyra J, Montero C, Weaver M, Yang K, Mahler S. Evaluation of European Society of Cardiology (ESC) 0/1-hour algorithm in the diagnosis of 90-day major adverse cardiovascular events: a multicenter United States cohort study. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1671] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
The ESC 0/1-hour algorithm using high sensitivity troponin (ESC 0/1-h) is a rapid triage protocol for diagnosing acute coronary syndrome, however the classification performance of the algorithm in the US population is uncertain. Further, evidence for the use of ESC 0/1-h in the long-term diagnosis of major adverse cardiovascular events (MACE) remains limited.
Purpose
To evaluate the performance of the ESC 0/1-h algorithm in diagnosing 90-day MACE in a diverse US cohort.
Methods
In this prospective, multicenter, observational cohort study, adult emergency department patients who were evaluated for suspected ACS were enrolled at eight sites in the US. Serial 1-hour blood samples were collected and high sensitivity troponin T (hs-cTnT) concentrations were measured in a central laboratory using the hs-cTnT assay. Primary outcome included major adverse cardiovascular events (MACE) within 90 (+30) days of enrollment. MACE defined as myocardial infarction (MI), cardiovascular or uncertain death, and coronary revascularization. Presence of MI and cardiovascular death were adjudicated by independent reviewers blinded to hs-cTnT results. Each participant was stratified to one of three risk groups as determined by ESC 0/1-h algorithm. Diagnostic classification performance metrics with exact confidence intervals (i.e. negative predictive value [NPV], positive predicted value [PPV], sensitivity, and specificity) were evaluated for each risk group where appropriate.
Results
Among 1430 eligible participants, 45.8% (655/1430) were women and 36.6% (524/1430) were African American with a mean age of 57.6±12.8 years. MACE at 90-days occurred in 15.5% (221/1430). ESC 0/1-h stratified 59.5% (851/1430) subjects in Rule-Out range and 13.0% (186/1430) subjects in Rule-In range. The Rule-Out criteria had an NPV and sensitivity for 90-day MACE of 96.8% (95% CI: 95.4–97.9%) and 87.8% (95% CI: 82.7–91.8%), respectively. For 90-day cardiovascular death or MI, Rule-Out criteria had an NPV of 98.2% (95% CI: 97.1–99.0%) and sensitivity was 92.4% (95% CI: 87.8–95.7%). The Rule-In criteria had a PPV of 60.8% (95% CI: 53.3–67.8%) for both outcomes. Rule-In criteria had a specificity for 90-day MACE and 90-day cardiovascular death or MI of 94.0% (95% CI: 92.5–95.2%) and 94.1% (95% CI: 92.6–95.3%), respectively. Among the 27.5% (393/1430) participants classified in neither risk groups, the prevalence of 90-day MACE was 20.6% (81/393) and the prevalence of 90-day cardiovascular death or MI was 17.8% (70/393)
Conclusion
In a prospective, multicenter, US cohort, the ESC 0/1-h algorithm was unable to achieve a sufficiently high NPV to safely exclude the diagnosis of MACE within 90 days after emergency department presentation. New hs-cTn algorithms specific to the US population may be warranted.
ESC 0/1-h 90 Day Outcomes
Funding Acknowledgement
Type of funding source: Private company. Main funding source(s): Roche Diagnostics
Collapse
Affiliation(s)
- B Allen
- University of Florida, Emergency Medicine, Gainesville, United States of America
| | - R Christenson
- University of Maryland, Pathology, Baltimore, United States of America
| | - S Cohen
- University of Florida, Emergency Medicine, Gainesville, United States of America
| | - R Nowak
- Henry Ford Hospital, Emergency Medicine, Detroit, United States of America
| | - G Wilkerson
- University of Maryland, Emergency Medicine, Baltimore, United States of America
| | - B Mumma
- University of California, Emergency Medicine, Davis, United States of America
| | - T Madsen
- University of Utah, Emergency Medicine, Salt Lake City, United States of America
| | - J McCord
- Henry Ford Hospital, Cardiology, Detroit, United States of America
| | - M Huis In 'T Veld
- University of Maryland, Emergency Medicine, Baltimore, United States of America
| | - M Massoomi
- University of Florida, Cardiology, Gainesville, United States of America
| | - J Stopyra
- Wake Forest University, Emergency Medicine, Winston-Salem, United States of America
| | - C Montero
- University of Florida, Emergency Medicine, Gainesville, United States of America
| | - M Weaver
- University of Florida, Nursing and Biostatistics, Gainesville, United States of America
| | - K Yang
- University of Florida, Nursing and Biostatistics, Gainesville, United States of America
| | - S Mahler
- Wake Forest University, Emergency Medicine, Winston-Salem, United States of America
| |
Collapse
|
5
|
Montero C, Thompson NC. Anesthetic Management for a Pediatric Patient with Long QT Syndrome. J Natl Med Assoc 2020. [DOI: 10.1016/j.jnma.2020.09.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
6
|
Pastor D, Cervelló E, Peruyero F, Biddle S, Montero C. Acute physical exercise intensity, cognitive inhibition and psychological well-being in adolescent physical education students. Curr Psychol 2019. [DOI: 10.1007/s12144-019-00454-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
7
|
Argibay B, Campos F, Perez-Mato M, Vieites-Prado A, Correa-Paz C, López-Arias E, Da Silva-Candal A, Moreno V, Montero C, Sobrino T, Castillo J, Iglesias-Rey R. Light-Emitting Diode Photobiomodulation After Cerebral Ischemia. Front Neurol 2019; 10:911. [PMID: 31507516 PMCID: PMC6713875 DOI: 10.3389/fneur.2019.00911] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2019] [Accepted: 08/06/2019] [Indexed: 11/14/2022] Open
Abstract
Photobiomodulation (PBM) therapy is a promising therapeutic approach for several pathologies, including stroke. The biological effects of PBM for the treatment of cerebral ischemia have previously been explored as a neuroprotective strategy using different light sources, wavelengths, and incident light powers. However, the capability of PBM as a novel alternative therapy to stimulate the recovery of the injured neuronal tissue after ischemic stroke has been poorly explored. The aim of this study was to investigate the low-level light irradiation therapy by using Light Emitting Diodes (LEDs) as potential therapeutic strategy for stroke. The LED photobiomodulation (continuous wave, 830 nm, 0.2–0.6 J/cm2) was firstly evaluated at different energy densities in C17.2 immortalized mouse neural progenitor cell lines, in order to observe if this treatment had any effect on cells, in terms of proliferation and viability. Then, the PBM-LED effect (continuous wave, 830 nm, 0.28 J/cm2 at brain cortex) on long-term recovery (12 weeks) was analyzed in ischemic animal model by means lesion reduction, behavioral deficits, and functional magnetic resonance imaging (fMRI). Analysis of cellular proliferation after PBM was significantly increased (1 mW) in all different exposure times used; however, this effect could not be replicated in vivo experimental conditions, as PBM did not show an infarct reduction or functional recovery. Despite the promising therapeutic effect described for PBM, further preclinical studies are necessary to optimize the therapeutic window of this novel therapy, in terms of the mechanism associated to neurorecovery and to reduce the risk of failure in futures clinical trials.
Collapse
Affiliation(s)
- Bárbara Argibay
- Clinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), Clinical University Hospital, Universidade de Santiago de Compostela, Santiago de Compostela, Spain
| | - Francisco Campos
- Clinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), Clinical University Hospital, Universidade de Santiago de Compostela, Santiago de Compostela, Spain
| | - María Perez-Mato
- Clinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), Clinical University Hospital, Universidade de Santiago de Compostela, Santiago de Compostela, Spain
| | - Alba Vieites-Prado
- Clinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), Clinical University Hospital, Universidade de Santiago de Compostela, Santiago de Compostela, Spain
| | - Clara Correa-Paz
- Clinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), Clinical University Hospital, Universidade de Santiago de Compostela, Santiago de Compostela, Spain
| | - Esteban López-Arias
- Clinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), Clinical University Hospital, Universidade de Santiago de Compostela, Santiago de Compostela, Spain
| | - Andrés Da Silva-Candal
- Clinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), Clinical University Hospital, Universidade de Santiago de Compostela, Santiago de Compostela, Spain
| | - Vicente Moreno
- Optics Area, Department of Applied Physics, Faculty of Physics, Universitdade de Santiago de Compostela, Santiago de Compostela, Spain.,Faculty of Optics and Optometry, Universitdade de Santiago de Compostela, Santiago de Compostela, Spain
| | - Carlos Montero
- Optics Area, Department of Applied Physics, Faculty of Physics, Universitdade de Santiago de Compostela, Santiago de Compostela, Spain.,Faculty of Optics and Optometry, Universitdade de Santiago de Compostela, Santiago de Compostela, Spain
| | - Tomás Sobrino
- Clinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), Clinical University Hospital, Universidade de Santiago de Compostela, Santiago de Compostela, Spain
| | - José Castillo
- Clinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), Clinical University Hospital, Universidade de Santiago de Compostela, Santiago de Compostela, Spain
| | - Ramón Iglesias-Rey
- Clinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), Clinical University Hospital, Universidade de Santiago de Compostela, Santiago de Compostela, Spain
| |
Collapse
|
8
|
Ceballo Y, Tiel K, López A, Cabrera G, Pérez M, Ramos O, Rosabal Y, Montero C, Menassa R, Depicker A, Hernández A. High accumulation in tobacco seeds of hemagglutinin antigen from avian (H5N1) influenza. Transgenic Res 2017; 26:775-789. [PMID: 28986672 DOI: 10.1007/s11248-017-0047-9] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2017] [Accepted: 09/21/2017] [Indexed: 01/13/2023]
Abstract
Tobacco seeds can be used as a cost effective system for production of recombinant vaccines. Avian influenza is an important respiratory pathogen that causes a high degree of mortality and becomes a serious threat for the poultry industry. A safe vaccine against avian flu produced at low cost could help to prevent future outbreaks. We have genetically engineered tobacco plants to express extracellular domain of hemagglutinin protein from H5N1 avian influenza virus as an inexpensive alternative for production purposes. Two regulatory sequences of seed storage protein genes from Phaseolus vulgaris L. were used to direct the expression, yielding 3.0 mg of the viral antigen per g of seeds. The production and stability of seed-produced recombinant HA protein was characterized by different molecular techniques. The aqueous extract of tobacco seed proteins was used for subcutaneous immunization of chickens, which developed antibodies that inhibited the agglutination of erythrocytes after the second application of the antigen. The feasibility of using tobacco seeds as a vaccine carrier is discussed.
Collapse
Affiliation(s)
- Yanaysi Ceballo
- Plant Biotechnology Department, Center for Genetic Engineering and Biotechnology (CIGB), PO Box 6162, 10600, Havana, Havana, Cuba.
| | - Kenia Tiel
- Plant Biotechnology Department, Center for Genetic Engineering and Biotechnology (CIGB), PO Box 6162, 10600, Havana, Havana, Cuba
| | - Alina López
- Plant Biotechnology Department, Center for Genetic Engineering and Biotechnology (CIGB), PO Box 6162, 10600, Havana, Havana, Cuba
| | - Gleysin Cabrera
- Department of Carbohydrate Chemistry, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba
| | - Marlene Pérez
- Plant Biotechnology Department, Center for Genetic Engineering and Biotechnology (CIGB), PO Box 6162, 10600, Havana, Havana, Cuba
| | - Osmany Ramos
- Plant Biotechnology Department, Center for Genetic Engineering and Biotechnology (CIGB), PO Box 6162, 10600, Havana, Havana, Cuba
| | - Yamilka Rosabal
- Plant Biotechnology Department, Center for Genetic Engineering and Biotechnology (CIGB), PO Box 6162, 10600, Havana, Havana, Cuba
| | - Carlos Montero
- Animal Biotechnology Department, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba
| | - Rima Menassa
- London Research and Development Centre, Agriculture and Agri-Food Canada, London, ON, Canada
| | - Ann Depicker
- Department Plant Biotechnology and Bioinformatics, Ghent University, Ghent, Belgium
- Department Plant Systems Biologie, VIB, Ghent, Belgium
| | - Abel Hernández
- Plant Biotechnology Department, Center for Genetic Engineering and Biotechnology (CIGB), PO Box 6162, 10600, Havana, Havana, Cuba
| |
Collapse
|
9
|
Kohler J, Gavegnano C, Kohler J, Montero C, Schinazi R. Novel mechanisms of baricitinib to block reservoir seeding and HIV persistence. J Virus Erad 2017. [DOI: 10.1016/s2055-6640(20)30678-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
10
|
Gavegnano C, Haile W, Montero C, Tyor W, Schinazi F. In vitro and in vivo quantification of HIV-induced neuroinflammation and effect of antiviral agents in primary human microglia and a murine HAND model. J Virus Erad 2017. [DOI: 10.1016/s2055-6640(20)30603-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
11
|
Affiliation(s)
| | - J. C. Gallego
- Department of Radiology, Thoracic Surgery, and Respiratory Medicine, Hospital Juan Canalejo, Xubias de Arriba 84, E-15006 La Coruña, Spain
| | | | | | | |
Collapse
|
12
|
Suarez M, Rubi J, Pérez D, Cordova V, Salazar Y, Vielma A, Barrios F, Gil CA, Segura N, Carrillo Y, Cartaya R, Palacios M, Rubio E, Escalona C, Ramirez RC, Baker RB, Machado H, Sordo Y, Bermudes J, Vargas M, Montero C, Cruz A, Puente P, Rodriguez JL, Mantilla E, Oliva O, Smith E, Castillo A, Ramos B, Ramirez Y, Abad Z, Morales A, Gonzalez EM, Hernandez A, Ceballo Y, Callard D, Cardoso A, Navarro M, Gonzalez JL, Pina R, Cueto M, Borroto C, Pimentel E, Carpio Y, Estrada MP. High impact and effectiveness of Gavac™ vaccine in the national program for control of bovine ticks Rhipicephalus microplus in Venezuela. Livest Sci 2016. [DOI: 10.1016/j.livsci.2016.02.005] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
13
|
Monn JA, Prieto L, Taboada L, Hao J, Reinhard MR, Henry SS, Beadle CD, Walton L, Man T, Rudyk H, Clark B, Tupper D, Baker SR, Lamas C, Montero C, Marcos A, Blanco J, Bures M, Clawson DK, Atwell S, Lu F, Wang J, Russell M, Heinz BA, Wang X, Carter JH, Getman BG, Catlow JT, Swanson S, Johnson BG, Shaw DB, McKinzie DL. Synthesis and Pharmacological Characterization of C4-(Thiotriazolyl)-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1R,2S,4R,5R,6R)-2-Amino-4-(1H-1,2,4-triazol-3-ylsulfanyl)bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2812223), a Highly Potent, Functionally Selective mGlu2 Receptor Agonist. J Med Chem 2015; 58:7526-48. [PMID: 26313429 DOI: 10.1021/acs.jmedchem.5b01124] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Identification of orthosteric mGlu(2/3) receptor agonists capable of discriminating between individual mGlu2 and mGlu3 subtypes has been highly challenging owing to the glutamate-site sequence homology between these proteins. Herein we detail the preparation and characterization of a series of molecules related to (1S,2S,5R,6S)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate 1 (LY354740) bearing C4-thiotriazole substituents. On the basis of second messenger responses in cells expressing other recombinant human mGlu2/3 subtypes, a number of high potency and efficacy mGlu2 receptor agonists exhibiting low potency mGlu3 partial agonist/antagonist activity were identified. From this, (1R,2S,4R,5R,6R)-2-amino-4-(1H-1,2,4-triazol-3-ylsulfanyl)bicyclo[3.1.0]hexane-2,6-dicarboxylic acid 14a (LY2812223) was further characterized. Cocrystallization of 14a with the amino terminal domains of hmGlu2 and hmGlu3 combined with site-directed mutation studies has clarified the underlying molecular basis of this unique pharmacology. Evaluation of 14a in a rat model responsive to mGlu2 receptor activation coupled with a measure of central drug disposition provides evidence that this molecule engages and activates central mGlu2 receptors in vivo.
Collapse
Affiliation(s)
- James A Monn
- Discovery Chemistry Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition and ⊥Neuroscience Research, Eli Lilly and Company , Lilly Corporate Center, Drop 0510, Indianapolis, Indiana 46285, United States
| | - Lourdes Prieto
- Discovery Chemistry Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition and ⊥Neuroscience Research, Eli Lilly and Company , Lilly Corporate Center, Drop 0510, Indianapolis, Indiana 46285, United States
| | - Lorena Taboada
- Discovery Chemistry Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition and ⊥Neuroscience Research, Eli Lilly and Company , Lilly Corporate Center, Drop 0510, Indianapolis, Indiana 46285, United States
| | - Junliang Hao
- Discovery Chemistry Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition and ⊥Neuroscience Research, Eli Lilly and Company , Lilly Corporate Center, Drop 0510, Indianapolis, Indiana 46285, United States
| | - Matthew R Reinhard
- Discovery Chemistry Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition and ⊥Neuroscience Research, Eli Lilly and Company , Lilly Corporate Center, Drop 0510, Indianapolis, Indiana 46285, United States
| | - Steven S Henry
- Discovery Chemistry Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition and ⊥Neuroscience Research, Eli Lilly and Company , Lilly Corporate Center, Drop 0510, Indianapolis, Indiana 46285, United States
| | - Christopher D Beadle
- Discovery Chemistry Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition and ⊥Neuroscience Research, Eli Lilly and Company , Lilly Corporate Center, Drop 0510, Indianapolis, Indiana 46285, United States
| | - Lesley Walton
- Discovery Chemistry Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition and ⊥Neuroscience Research, Eli Lilly and Company , Lilly Corporate Center, Drop 0510, Indianapolis, Indiana 46285, United States
| | - Teresa Man
- Discovery Chemistry Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition and ⊥Neuroscience Research, Eli Lilly and Company , Lilly Corporate Center, Drop 0510, Indianapolis, Indiana 46285, United States
| | - Helene Rudyk
- Discovery Chemistry Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition and ⊥Neuroscience Research, Eli Lilly and Company , Lilly Corporate Center, Drop 0510, Indianapolis, Indiana 46285, United States
| | - Barry Clark
- Discovery Chemistry Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition and ⊥Neuroscience Research, Eli Lilly and Company , Lilly Corporate Center, Drop 0510, Indianapolis, Indiana 46285, United States
| | - David Tupper
- Discovery Chemistry Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition and ⊥Neuroscience Research, Eli Lilly and Company , Lilly Corporate Center, Drop 0510, Indianapolis, Indiana 46285, United States
| | - S Richard Baker
- Discovery Chemistry Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition and ⊥Neuroscience Research, Eli Lilly and Company , Lilly Corporate Center, Drop 0510, Indianapolis, Indiana 46285, United States
| | - Carlos Lamas
- Discovery Chemistry Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition and ⊥Neuroscience Research, Eli Lilly and Company , Lilly Corporate Center, Drop 0510, Indianapolis, Indiana 46285, United States
| | - Carlos Montero
- Discovery Chemistry Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition and ⊥Neuroscience Research, Eli Lilly and Company , Lilly Corporate Center, Drop 0510, Indianapolis, Indiana 46285, United States
| | - Alicia Marcos
- Discovery Chemistry Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition and ⊥Neuroscience Research, Eli Lilly and Company , Lilly Corporate Center, Drop 0510, Indianapolis, Indiana 46285, United States
| | - Jaime Blanco
- Discovery Chemistry Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition and ⊥Neuroscience Research, Eli Lilly and Company , Lilly Corporate Center, Drop 0510, Indianapolis, Indiana 46285, United States
| | - Mark Bures
- Discovery Chemistry Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition and ⊥Neuroscience Research, Eli Lilly and Company , Lilly Corporate Center, Drop 0510, Indianapolis, Indiana 46285, United States
| | - David K Clawson
- Discovery Chemistry Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition and ⊥Neuroscience Research, Eli Lilly and Company , Lilly Corporate Center, Drop 0510, Indianapolis, Indiana 46285, United States
| | - Shane Atwell
- Discovery Chemistry Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition and ⊥Neuroscience Research, Eli Lilly and Company , Lilly Corporate Center, Drop 0510, Indianapolis, Indiana 46285, United States
| | - Frances Lu
- Discovery Chemistry Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition and ⊥Neuroscience Research, Eli Lilly and Company , Lilly Corporate Center, Drop 0510, Indianapolis, Indiana 46285, United States
| | - Jing Wang
- Discovery Chemistry Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition and ⊥Neuroscience Research, Eli Lilly and Company , Lilly Corporate Center, Drop 0510, Indianapolis, Indiana 46285, United States
| | - Marijane Russell
- Discovery Chemistry Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition and ⊥Neuroscience Research, Eli Lilly and Company , Lilly Corporate Center, Drop 0510, Indianapolis, Indiana 46285, United States
| | - Beverly A Heinz
- Discovery Chemistry Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition and ⊥Neuroscience Research, Eli Lilly and Company , Lilly Corporate Center, Drop 0510, Indianapolis, Indiana 46285, United States
| | - Xushan Wang
- Discovery Chemistry Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition and ⊥Neuroscience Research, Eli Lilly and Company , Lilly Corporate Center, Drop 0510, Indianapolis, Indiana 46285, United States
| | - Joan H Carter
- Discovery Chemistry Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition and ⊥Neuroscience Research, Eli Lilly and Company , Lilly Corporate Center, Drop 0510, Indianapolis, Indiana 46285, United States
| | - Brian G Getman
- Discovery Chemistry Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition and ⊥Neuroscience Research, Eli Lilly and Company , Lilly Corporate Center, Drop 0510, Indianapolis, Indiana 46285, United States
| | - John T Catlow
- Discovery Chemistry Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition and ⊥Neuroscience Research, Eli Lilly and Company , Lilly Corporate Center, Drop 0510, Indianapolis, Indiana 46285, United States
| | - Steven Swanson
- Discovery Chemistry Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition and ⊥Neuroscience Research, Eli Lilly and Company , Lilly Corporate Center, Drop 0510, Indianapolis, Indiana 46285, United States
| | - Bryan G Johnson
- Discovery Chemistry Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition and ⊥Neuroscience Research, Eli Lilly and Company , Lilly Corporate Center, Drop 0510, Indianapolis, Indiana 46285, United States
| | - David B Shaw
- Discovery Chemistry Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition and ⊥Neuroscience Research, Eli Lilly and Company , Lilly Corporate Center, Drop 0510, Indianapolis, Indiana 46285, United States
| | - David L McKinzie
- Discovery Chemistry Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition and ⊥Neuroscience Research, Eli Lilly and Company , Lilly Corporate Center, Drop 0510, Indianapolis, Indiana 46285, United States
| |
Collapse
|
14
|
Briere DA, Ruan X, Cheng CC, Siesky AM, Fitch TE, Dominguez C, Sanfeliciano SG, Montero C, Suen CS, Xu Y, Coskun T, Michael MD. Novel Small Molecule Agonist of TGR5 Possesses Anti-Diabetic Effects but Causes Gallbladder Filling in Mice. PLoS One 2015; 10:e0136873. [PMID: 26312995 PMCID: PMC4551797 DOI: 10.1371/journal.pone.0136873] [Citation(s) in RCA: 55] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2015] [Accepted: 08/09/2015] [Indexed: 12/25/2022] Open
Abstract
Activation of TGR5 via bile acids or bile acid analogs leads to the release of glucagon-like peptide-1 (GLP-1) from intestine, increases energy expenditure in brown adipose tissue, and increases gallbladder filling with bile. Here, we present compound 18, a non-bile acid agonist of TGR5 that demonstrates robust GLP-1 secretion in a mouse enteroendocrine cell line yet weak GLP-1 secretion in a human enteroendocrine cell line. Acute administration of compound 18 to mice increased GLP-1 and peptide YY (PYY) secretion, leading to a lowering of the glucose excursion in an oral glucose tolerance test (OGTT), while chronic administration led to weight loss. In addition, compound 18 showed a dose-dependent increase in gallbladder filling. Lastly, compound 18 failed to show similar pharmacological effects on GLP-1, PYY, and gallbladder filling in Tgr5 knockout mice. Together, these results demonstrate that compound 18 is a mouse-selective TGR5 agonist that induces GLP-1 and PYY secretion, and lowers the glucose excursion in an OGTT, but only at doses that simultaneously induce gallbladder filling. Overall, these data highlight the benefits and potential risks of using TGR5 agonists to treat diabetes and metabolic diseases.
Collapse
Affiliation(s)
- Daniel A. Briere
- Lilly Research Laboratories, Eli Lilly and Co., Indianapolis, Indiana, United States of America
| | - Xiaoping Ruan
- Lilly Research Laboratories, Eli Lilly and Co., Indianapolis, Indiana, United States of America
| | - Christine C. Cheng
- Lilly Research Laboratories, Eli Lilly and Co., Indianapolis, Indiana, United States of America
| | - Angela M. Siesky
- Lilly Research Laboratories, Eli Lilly and Co., Indianapolis, Indiana, United States of America
| | - Thomas E. Fitch
- Lilly Research Laboratories, Eli Lilly and Co., Indianapolis, Indiana, United States of America
| | - Carmen Dominguez
- Centro de Investigación, Eli Lilly and Company, Alcobendas, Spain
| | | | - Carlos Montero
- Centro de Investigación, Eli Lilly and Company, Alcobendas, Spain
| | - Chen S. Suen
- Lilly Research Laboratories, Eli Lilly and Co., Indianapolis, Indiana, United States of America
| | - Yanping Xu
- Lilly Research Laboratories, Eli Lilly and Co., Indianapolis, Indiana, United States of America
| | - Tamer Coskun
- Lilly Research Laboratories, Eli Lilly and Co., Indianapolis, Indiana, United States of America
| | - M. Dodson Michael
- Lilly Research Laboratories, Eli Lilly and Co., Indianapolis, Indiana, United States of America
- * E-mail:
| |
Collapse
|
15
|
Ip E, Milione G, Li MJ, Cvijetic N, Kanonakis K, Stone J, Peng G, Prieto X, Montero C, Moreno V, Liñares J. SDM transmission of real-time 10GbE traffic using commercial SFP + transceivers over 0.5km elliptical-core few-mode fiber. Opt Express 2015; 23:17120-17126. [PMID: 26191720 DOI: 10.1364/oe.23.017120] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
We experimentally demonstrate the first few-mode space division multiplexed (SDM) transmission of real-time 10Gb/s Ethernet (10GbE) traffic using commercial small form-factor pluggable SFP + transceivers without coherent detection or multiple input multiple output digital signal processing (MIMO-DSP) over 0.5km elliptical-core few-mode-fiber, achieving <-26dB crosstalk between LP(11e) and LP(11o) modes at 1.3μm.
Collapse
|
16
|
Monn JA, Prieto L, Taboada L, Pedregal C, Hao J, Reinhard MR, Henry SS, Goldsmith PJ, Beadle CD, Walton L, Man T, Rudyk H, Clark B, Tupper D, Baker SR, Lamas C, Montero C, Marcos A, Blanco J, Bures M, Clawson DK, Atwell S, Lu F, Wang J, Russell M, Heinz BA, Wang X, Carter JH, Xiang C, Catlow JT, Swanson S, Sanger H, Broad LM, Johnson MP, Knopp KL, Simmons RMA, Johnson BG, Shaw DB, McKinzie DL. Synthesis and Pharmacological Characterization of C4-Disubstituted Analogs of 1S,2S,5R,6S-2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylate: Identification of a Potent, Selective Metabotropic Glutamate Receptor Agonist and Determination of Agonist-Bound Human mGlu2 and mGlu3 Amino Terminal Domain Structures. J Med Chem 2015; 58:1776-94. [DOI: 10.1021/jm501612y] [Citation(s) in RCA: 49] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- James A. Monn
- Discovery Chemistry
Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition,
and ⊥Neuroscience
Research, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Lourdes Prieto
- Discovery Chemistry
Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition,
and ⊥Neuroscience
Research, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Lorena Taboada
- Discovery Chemistry
Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition,
and ⊥Neuroscience
Research, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Concepcion Pedregal
- Discovery Chemistry
Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition,
and ⊥Neuroscience
Research, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Junliang Hao
- Discovery Chemistry
Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition,
and ⊥Neuroscience
Research, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Matt R. Reinhard
- Discovery Chemistry
Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition,
and ⊥Neuroscience
Research, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Steven S. Henry
- Discovery Chemistry
Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition,
and ⊥Neuroscience
Research, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Paul J. Goldsmith
- Discovery Chemistry
Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition,
and ⊥Neuroscience
Research, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Christopher D. Beadle
- Discovery Chemistry
Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition,
and ⊥Neuroscience
Research, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Lesley Walton
- Discovery Chemistry
Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition,
and ⊥Neuroscience
Research, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Teresa Man
- Discovery Chemistry
Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition,
and ⊥Neuroscience
Research, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Helene Rudyk
- Discovery Chemistry
Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition,
and ⊥Neuroscience
Research, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Barry Clark
- Discovery Chemistry
Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition,
and ⊥Neuroscience
Research, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - David Tupper
- Discovery Chemistry
Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition,
and ⊥Neuroscience
Research, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - S. Richard Baker
- Discovery Chemistry
Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition,
and ⊥Neuroscience
Research, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Carlos Lamas
- Discovery Chemistry
Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition,
and ⊥Neuroscience
Research, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Carlos Montero
- Discovery Chemistry
Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition,
and ⊥Neuroscience
Research, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Alicia Marcos
- Discovery Chemistry
Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition,
and ⊥Neuroscience
Research, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Jaime Blanco
- Discovery Chemistry
Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition,
and ⊥Neuroscience
Research, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Mark Bures
- Discovery Chemistry
Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition,
and ⊥Neuroscience
Research, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - David K. Clawson
- Discovery Chemistry
Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition,
and ⊥Neuroscience
Research, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Shane Atwell
- Discovery Chemistry
Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition,
and ⊥Neuroscience
Research, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Frances Lu
- Discovery Chemistry
Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition,
and ⊥Neuroscience
Research, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Jing Wang
- Discovery Chemistry
Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition,
and ⊥Neuroscience
Research, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Marijane Russell
- Discovery Chemistry
Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition,
and ⊥Neuroscience
Research, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Beverly A. Heinz
- Discovery Chemistry
Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition,
and ⊥Neuroscience
Research, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Xushan Wang
- Discovery Chemistry
Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition,
and ⊥Neuroscience
Research, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Joan H. Carter
- Discovery Chemistry
Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition,
and ⊥Neuroscience
Research, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Chuanxi Xiang
- Discovery Chemistry
Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition,
and ⊥Neuroscience
Research, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - John T. Catlow
- Discovery Chemistry
Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition,
and ⊥Neuroscience
Research, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Steven Swanson
- Discovery Chemistry
Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition,
and ⊥Neuroscience
Research, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Helen Sanger
- Discovery Chemistry
Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition,
and ⊥Neuroscience
Research, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Lisa M. Broad
- Discovery Chemistry
Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition,
and ⊥Neuroscience
Research, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Michael P. Johnson
- Discovery Chemistry
Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition,
and ⊥Neuroscience
Research, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Kelly L. Knopp
- Discovery Chemistry
Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition,
and ⊥Neuroscience
Research, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Rosa M. A. Simmons
- Discovery Chemistry
Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition,
and ⊥Neuroscience
Research, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Bryan G. Johnson
- Discovery Chemistry
Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition,
and ⊥Neuroscience
Research, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - David B. Shaw
- Discovery Chemistry
Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition,
and ⊥Neuroscience
Research, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - David L. McKinzie
- Discovery Chemistry
Research and Technologies, ‡Quantitative Biology, §Structural Biology, ∥Drug Disposition,
and ⊥Neuroscience
Research, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| |
Collapse
|
17
|
Vincent HK, Montero C, Conrad BP, Seay A, Edenfield K, Vincent KR. Metabolic responses of running shod and barefoot in mid-forefoot runners. J Sports Med Phys Fitness 2014; 54:447-455. [PMID: 24777114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
BACKGROUND The purposes of this study were to compare the oxygen cost, metabolic parameters and temporalspatial variables between barefoot and shod running in trained mid-forefoot runners. METHODS Experienced runners (N.=21; 30±10.9 years; 16 men) performed two separate 20 minute treadmill running bouts at ~77% of estimated maximal heart rate. Rate of oxygen consumption (VO2), energy cost, fuel use and heart rate (HR) were collected continuously using a portable gas analyzer. Three-dimensional motion capture was used to measure temporalspatial parameters. RESULTS Participants ran at a mean self-selected speed of 3.1±0.3 m/s for both conditions, at intensities corresponding to mean HR values of 146 bpm (shod) and 144 bpm (barefoot). Steady State VO2 was not different between the shod and barefoot conditions (39.4± 4.7 mL/kg*min vs. 40±5.2 mL/kg*min, respectively). The total energy expended in the shod and barefoot conditions was 974±134 kJ and 979±142 kJ. The average non-protein respiratory exchange ratios, proportions and amount of fat and carbohydrate used were not different between conditions. Cadence was 2.5% higher and center of gravity vertical displacement was 0.5 cm less for the barefoot condition (P<0.05). CONCLUSION In trained mid-forefoot runners experienced with barefoot running, there are not significant metabolic differences between shod and barefoot running conditions. Barefoot running increases cadence and decreases foot contact time and vertical displacement. Experienced participants were likely able to titrate kinematics to standardize energy output and fuel use for a given running distance and speed irrespective of shoe wear.
Collapse
Affiliation(s)
- H K Vincent
- Department of Orthopedics and Rehabilitation Interdisciplinary Center for Musculoskeletal Training and Research Divisions of Research Physical Medicine and Rehabilitation and Sports Medicine, Gainesville, FL, USA -
| | | | | | | | | | | |
Collapse
|
18
|
Montero C, Navío R, Llorente P, Romero M, Martínez J. CRS Sales: Abengoa's Molten Salt Pilot Power Tower Plant Celebrates One Year of Uninterrupted Operation. ACTA ACUST UNITED AC 2014. [DOI: 10.1016/j.egypro.2014.03.052] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
19
|
Vincent HK, Seay AN, Montero C, Vincent KR. Outpatient rehabilitation outcomes in obese patients with orthopedic conditions. Eur J Phys Rehabil Med 2013; 49:419-429. [PMID: 23736903] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
BACKGROUND Obesity is related to the development of functional and mobility impairment, musculoskeletal pain and orthopedic problems. Irrespective of age, obese children and adults have impaired walking capacity and body transfer ability, and difficulties navigating obstacle courses or community spaces. Obesity is related to relative strength deficits, musculoskeletal pain, kinesiophobia, low self-efficacy and a decline in quality of life. AIM This review provides an update of the available evidence for the efficacy of outpatient rehabilitation programs for the treatment of disabling obesity. RESULTS Outpatient rehabilitation programs can effectively improve muscle strength, self-confidence and physical function. Key rehabilitation components should include aerobic exercise (AX), resistance exercise (RX) and cognitive strategies to cope with the unique challenges posed by obesity. Available high quality evidence indicates that 3-18 month rehabilitation programs that included aerobic and strengthening exercise (2-3 days per week) with caloric restriction (typically 500-750 kcal deficit/ day), elicited the best changes in functional performance measures compared with exercise or diet alone. CONCLUSION Comprehensive outpatient rehabilitation interventions coupled with diet can catalyze lifestyle patterns that improve and preserve physical function over the life span.
Collapse
Affiliation(s)
- H K Vincent
- Divisions of Research, Department of Orthopedics and Rehabilitation Interdisciplinary Center for Musculoskeletal Training and Research, University of Florida, Gainesville, FL 32611, USA.
| | | | | | | |
Collapse
|
20
|
Protti M, McNally K, Pacheco J, González V, Montero C, Segura J, Brenes J, Barboza V, Malavassi E, Güendel F, Simila G, Rojas D, Velasco A, Mata A, Schillinger W. The March 25, 1990 (Mw= 7.0, ML= 6.8), earthquake at the entrance of the Nicoya Gulf, Costa Rica: Its prior activity, foreshocks, aftershocks, and triggered seismicity. ACTA ACUST UNITED AC 2012. [DOI: 10.1029/94jb03099] [Citation(s) in RCA: 62] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
21
|
Rodríguez-Valle M, Taoufik A, Valdés M, Montero C, Hassan I, Hassan SM, Jongejan F, de la Fuente J. Efficacy of Rhipicephalus (Boophilus) microplus Bm86 against Hyalomma dromedarii and Amblyomma cajennense tick infestations in camels and cattle. Vaccine 2012; 30:3453-8. [DOI: 10.1016/j.vaccine.2012.03.020] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2012] [Revised: 02/13/2012] [Accepted: 03/08/2012] [Indexed: 02/05/2023]
|
22
|
Bai N, Ip E, Huang YK, Mateo E, Yaman F, Li MJ, Bickham S, Ten S, Liñares J, Montero C, Moreno V, Prieto X, Tse V, Man Chung K, Lau APT, Tam HY, Lu C, Luo Y, Peng GD, Li G, Wang T. Mode-division multiplexed transmission with inline few-mode fiber amplifier. Opt Express 2012; 20:2668-2680. [PMID: 22330504 DOI: 10.1364/oe.20.002668] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
We demonstrate mode-division multiplexed WDM transmission over 50-km of few-mode fiber using the fiber's LP01 and two degenerate LP11 modes. A few-mode EDFA is used to boost the power of the output signal before a few-mode coherent receiver. A 6×6 time-domain MIMO equalizer is used to recover the transmitted data. We also experimentally characterize the 50-km few-mode fiber and the few-mode EDFA.
Collapse
Affiliation(s)
- Neng Bai
- NEC Labs America, 4 Independence Way, Princeton, NJ 08540, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Gamboa O, Montero C, Mesa L, Benavides C, Reino A, Torres R, Castillo J. Cost-Effectiveness Analysis of the Early Conversion of Tacrolimus to Mammalian Target of Rapamycin Inhibitors in Patients with Renal Transplantation. Transplant Proc 2011; 43:3367-76. [DOI: 10.1016/j.transproceed.2011.09.092] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
24
|
del Carmen Rial M, Abbud-Filho M, Torres Gonçalves R, Martinez-Mier G, Montero C, Raffaele P, Toledo Solares M, Alberú J. Individualizing Early Use of Sirolimus in Renal Transplantation. Transplant Proc 2010; 42:4518-25. [DOI: 10.1016/j.transproceed.2010.10.015] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2010] [Accepted: 10/07/2010] [Indexed: 12/30/2022]
|
25
|
Vargas M, Montero C, Sánchez D, Pérez D, Valdés M, Alfonso A, Joglar M, Machado H, Rodríguez E, Méndez L, Lleonart R, Suárez M, Fernández E, Estrada MP, Rodríguez-Mallón A, Farnós O. Two initial vaccinations with the Bm86-based Gavacplus vaccine against Rhipicephalus (Boophilus) microplus induce similar reproductive suppression to three initial vaccinations under production conditions. BMC Vet Res 2010; 6:43. [PMID: 20846415 PMCID: PMC2949828 DOI: 10.1186/1746-6148-6-43] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2009] [Accepted: 09/16/2010] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND The cattle tick, Rhipicephalus (Boophilus) microplus, affects livestock production in many regions of the world. Up to now, the widespread use of chemical acaricides has led to the selection of acaricide-resistant ticks and to environmental contamination. Gavacplus is a subunit vaccine based on the recombinant Bm86 tick antigen expressed in yeast, capable to control infestations of R. microplus under controlled and production conditions. The vaccine constitutes the core element of broad control programs against this ectoparasite, in which acquired immunity in cattle to Bm86 is combined with a rational use of acaricides. At present, the conventional vaccine scheme consists of three doses that should be administered at weeks 0, 4 and 7, followed by a booster every six months. RESULTS In this study we assayed a reduction in the number of the initial doses of Gavacplus, evaluated the time course and the level of bovine anti-Bm86 antibodies elicited, and analyzed the vaccine effect on ticks engorging on immunized cattle under production conditions. Following three different immunization schemes, the bovines developed a strong and specific immune response characterized by elevated anti-Bm86 IgG titers. A reduction in the weight of engorging female ticks, in the weight of the eggs laid and also in R. microplus viable eggs percentage was obtained by using only two doses of Gavacplus administered at weeks 0 and 4, followed by a booster six months later. This reduction did not differ from the results obtained on ticks engorging on cattle immunized at weeks 0, 4 and 7. It was also demonstrated that anti-Bm86 antibody titers over 1:640, measured in bovines immunized at weeks 0 and 4, were sufficient to affect weight and reproductive potential of female ticks as compared with ticks engorging on unvaccinated animals. In addition, no statistically significant differences were detected in the average weight of eggs laid by ticks engorged on immunized cattle that showed anti-Bm86 specific titers in the range of 1:640 to 1:81920. CONCLUSION The administration of two initial doses of Gavacplus containing 100 μg of Bm86 antigen to non-immunized cattle under production conditions is sufficient to affect the weight and the reproductive capacity of R. microplus engorging females. According to these results, cattle herds' manipulation and vaccine costs could be potentially reduced with a positive impact on the implementation of integrated control programs against R. microplus.
Collapse
Affiliation(s)
- Milagros Vargas
- Clinical Trials Department, Center for Genetic Engineering and Biotechnology, 31th Avenue and 190, Havana 10600, Cuba
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Montero C, Gril J, Clair B. Interaction between mechanosorptive and viscoelastic response of wood at high humidity level. EPJ Web of Conferences 2010. [DOI: 10.1051/epjconf/20100628004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
27
|
Cordero R, Montero C. Obtention production and use of factor VIII in Costa Rica. Scand J Haematol Suppl 2009; 40:509-11. [PMID: 6433473 DOI: 10.1111/j.1600-0609.1984.tb02610.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
28
|
Abstract
The aim of this study was to describe the occurrence of acute coronary syndromes in 3 cases of rituximab infusions. We reviewed the records of 3 patients with lymphoproliferative disorders who experienced acute coronary syndromes associated with their initial infusion of rituximab. All 3 patients received rituximab according to a standardized institutional rate schedule, and all received pre-medication with acetaminophen and diphenhydramine. The median age of patients was 61 years. One patient had known atherosclerotic heart disease, and 2 patients had risk factors for coronary artery disease. All patients had varying degrees of evidenced high tumor burden, including lymphocytosis, elevated lactate dehydrogenase values, bulky tumor masses, and bone marrow involvement by lymphoma. All 3 patients experienced fairly typical chest pain syndromes and experienced elevations of cardiac enzymes consistent with myocardial ischemia. One patient died of an arrhythmia that deteriorated into asystole, and 2 patients recovered and underwent coronary angiography. Acute coronary syndromes can be associated with the infusion of rituximab. Patients with a history of previous coronary artery disease or risk factors for coronary artery disease should be observed closely for signs of myocardial ischemia, particularly during the initial infusion. The occurrence of symptoms that could be ascribed to an acute coronary syndrome should always be taken seriously during the first rituximab infusion and investigated aggressively. Patients should be aware that this is a rare, albeit serious, complication of treatment with rituximab.
Collapse
Affiliation(s)
- Joel D Armitage
- Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA
| | | | | | | | | |
Collapse
|
29
|
|
30
|
Ramon-Pardo P, Jacquet V, Armengol R, Montero C, Echegaray E, Del Granado MV. Scaling up collaborative TB-HIV activities in Latin America. Int J Tuberc Lung Dis 2008; 12:51-53. [PMID: 18302823] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023] Open
Abstract
TB-HIV collaborative activities are one of the cornerstones of TB control in the Stop TB strategy. Since 2003, most countries in Latin America and the Caribbean have been gradually implementing TB-HIV collaborative activities; however, limited information is currently available on the degree of implementation. This study is therefore aimed at describing to what degree TB-HIV collaborative activities are being implemented in 17 countries selected for the study. These countries were asked to complete a semi-structured questionnaire. An analysis of this questionnaire revealed that the challenges for TB-HIV collaboration lie in the fields of human resources, surveillance and HIV testing of TB patients.
Collapse
Affiliation(s)
- P Ramon-Pardo
- Tuberculosis Program, Communicable Diseases Unit, Health Surveillance and Disease Management Area, Pan American Health Organization, Washington, DC, USA.
| | | | | | | | | | | |
Collapse
|
31
|
Sánchez-Blázquez P, Rodríguez-Muñoz M, Montero C, de la Torre-Madrid E, Garzón J. Calcium/calmodulin-dependent protein kinase II supports morphine antinociceptive tolerance by phosphorylation of glycosylated phosducin-like protein. Neuropharmacology 2007; 54:319-30. [PMID: 18006024 DOI: 10.1016/j.neuropharm.2007.10.002] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2007] [Revised: 09/10/2007] [Accepted: 10/01/2007] [Indexed: 12/13/2022]
Abstract
The long isoform of the phosducin-like protein (PhLPl) is widely expressed in the brain and it is thought to influence G-protein signalling by regulating the activity of Gbetagamma dimers. We show that in the mature nervous system, PhLPl exists as both a 38kDa non-glycosylated isoform and as glycosylated isoforms of about 45, 100 and 150kDa. Additionally, neural PhLPl is subject to serine phosphorylation, which augments upon the activation of Mu-opioid receptors (MORs), as does its association with Gbetagamma subunits and 14-3-3 proteins. While the intracerebroventricular (icv) administration of morphine to mice rapidly reduced the association of MORs with G proteins, it increased the serine phosphorylation of these receptors. Moreover, activated Ca2+/calmodulin-dependent protein kinase II (CaMKII) accumulated in the MOR environment and phosphorylated PhLPl was seen to co-precipitate with these opioid receptors. Opioid-induced phosphorylation of PhLPl was impaired by inhibiting the activity of CaMKII and, in these circumstances, the association of PhLPl with Gbetagamma dimers and 14-3-3 proteins was diminished. Furthermore, these events were coupled with the recovery of G protein regulation by the MORs, while there was a decrease in serine phosphorylation of these receptors and morphine antinociceptive tolerance diminished. It seems that CaMKII phosphorylation of PhLPl stabilizes the PhLPl.Gbetagamma complex by promoting its binding to 14-3-3 proteins. When this complex fails to bind to 14-3-3 proteins, the association of PhLPl with Gbetagamma is probably disrupted by GalphaGDP subunits and the MORs recover control on G proteins.
Collapse
|
32
|
Bueno AB, Gilmore J, Boot J, Broadmore R, Cooper J, Findlay J, Hayhurst L, Marcos A, Montero C, Mitchell S, Timms G, Tomlinson R, Wallace L, Walton L. Naphthyl piperazines with dual activity as 5-HT1D antagonists and 5-HT reuptake inhibitors. Bioorg Med Chem Lett 2007; 17:3344-8. [PMID: 17434731 DOI: 10.1016/j.bmcl.2007.03.101] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2007] [Revised: 03/28/2007] [Accepted: 03/30/2007] [Indexed: 11/16/2022]
Abstract
SAR around a known molecule with dual 5-HT(1D) antagonist and 5-HT(transporter) inhibitory activity has led to the discovery of molecules with improved dual activity and reduced cross-reactivity toward other aminergic receptors (5-HT(1B), alpha(1), and D(2)).
Collapse
Affiliation(s)
- Ana B Bueno
- Lilly SA, Avda. de la Industria, 30, 28108, Alcobendas, Madrid, Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Caceres J, Montero C, Morato M, González Ureña A. Interaction of a supersonic NO beam with a static and a resonant RF field: Measurement of rotationally resolved dipole moments. Chem Phys Lett 2006. [DOI: 10.1016/j.cplett.2006.06.004] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
34
|
Fernández de la Pradilla R, Alhambra C, Castellanos A, Fernández J, Manzano P, Montero C, Ureña M, Viso A. Reductive Cleavage of Tetrahydrofuryl Sulfur-Substituted Oxiranes: Application to the Formal Synthesis of Kumausyne and Kumausallene. J Org Chem 2005; 70:10693-700. [PMID: 16355987 DOI: 10.1021/jo051459k] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
[reactions: see text] Readily available sulfinyl and sulfonyl tetrahydrofuran methanol derivatives have been transformed efficiently into a variety of substituted tetrahydrofuryl alcohols by treatment with (PhSe)2 in the presence of an excess of NaBH4. Alternatively, oxirane cleavage with MgI2 produces the related ketones, amenable to stereocontrolled reduction. This reductive cleavage methodology has been applied to short formal syntheses of trans-Kumausyne and Kumausallene.
Collapse
|
35
|
Bueno AB, Flynn CJ, Gilmore J, Marcos A, Montero C, Porter W, Williams AC. A versatile protocol for the preparation of substituted 1- and 2-naphthyl piperazines from aminonaphthols. Tetrahedron Lett 2005. [DOI: 10.1016/j.tetlet.2005.09.052] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
36
|
Bueno AB, Collado I, de Dios A, Domínguez C, Martín JA, Martín LM, Martínez-Grau MA, Montero C, Pedregal C, Catlow J, Coffey DS, Clay MP, Dantzig AH, Lindstrom T, Monn JA, Jiang H, Schoepp DD, Stratford RE, Tabas LB, Tizzano JP, Wright RA, Herin MF. Dipeptides as effective prodrugs of the unnatural amino acid (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740), a selective group II metabotropic glutamate receptor agonist. J Med Chem 2005; 48:5305-20. [PMID: 16078848 DOI: 10.1021/jm050235r] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
(+)-2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (1), also known as LY354740, is a highly potent and selective agonist for group II metabotropic glutamate receptors (mGlu receptors 2 and 3) tested in clinical trials. It has been shown to block anxiety in the fear-potentiated startle model. Its relatively low bioavailability in different animal species drove the need for an effective prodrug form that would produce a therapeutic response at lower doses for the treatment of anxiety disorders. We have investigated the increase of intestinal absorption of this compound by targeting the human peptide transporter hPepT1 for active transport of di- and tripeptides derived from 1. We have found that oral administration of an N dipeptide derivative of 1 (12a) in rats shows up to an 8-fold increase in drug absorption and a 300-fold increase in potency in the fear-potentiated startle model in rats when compared with the parent drug 1.
Collapse
Affiliation(s)
- Ana Belén Bueno
- Lilly, S.A., Avda. de la Industria 30, 28108 Alcobendas, Madrid, Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Fernández de la Pradilla R, Montero C, Tortosa M, Viso A. Highly Diastereoselective Diels-Alder Reactions with Enantiopure Sulfinyl-Substituted 1-Hydroxymethyldienes. Chemistry 2005; 11:5136-45. [PMID: 16001390 DOI: 10.1002/chem.200500191] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Enantiopure hydroxy-2- and -3-sulfinyldienes undergo highly selective Diels-Alder cycloadditions with various dienophiles controlled by the chiral sulfur atom. The related hydroxy-2-sulfonyldienes display complementary pi-facial selectivity.
Collapse
|
38
|
Mandiola E, Alarcón E, del Sol M, Olave E, Montero C, Sanhueza P, Oñate JC. Análisis Biométrico de las Arterias Comunicante Anterior y Cerebral Anterior en el Segmento Precomunicante del Círculo Arterial Cerebral. INT J MORPHOL 2005. [DOI: 10.4067/s0717-95022005000200012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
39
|
Sánchez-Blázquez P, Rodríguez-Muñoz M, Montero C, Garzón J. RGS-Rz and RGS9-2 proteins control mu-opioid receptor desensitisation in CNS: the role of activated Galphaz subunits. Neuropharmacology 2005; 48:134-50. [PMID: 15617734 DOI: 10.1016/j.neuropharm.2004.08.016] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2004] [Revised: 07/29/2004] [Accepted: 08/17/2004] [Indexed: 11/21/2022]
Abstract
Two consecutive i.c.v. administrations of analgesic doses of mu-opioid receptor agonists lead to a profound desensitisation of the latter receptors; a third dose produced less than 20% of the effect obtained with the first administration. Desensitisation was still effective 24h later. Impairing the activity of Galphaz but not Galphai2 subunits prevented tolerance developing after the administration of three consecutive doses of morphine. Further, the i.c.v. injection of Galphai2 subunits potentiated morphine analgesia and abolished acute tolerance, whereas i.c.v.-administered Galphaz subunits produced a rapid and robust loss of the response to morphine. The RGSZ1 and RGSZ2 proteins selectively deactivate GalphazGTP subunits, and their knockdown increased the effects produced by the first dose of morphine. However, impairing their activity also accelerated tachyphylaxis following successive doses of morphine, and facilitated the development of acute morphine tolerance. In contrast, inhibiting the RGS9-2 proteins, which bind to GalphaoGTP and GalphaiGTP but only weakly deactivates them, preserved the effects of consecutive morphine doses and abolished the generation of acute tolerance. Therefore, desensitisation of mu-opioid receptors can be achieved by reducing the responsiveness of post-receptor elements (via the possible action of activated Galphaz subunits) and/or by depleting the pool of receptor-regulated G proteins that agonists need to propagate their effects, e.g., through the activity of RGS9-2 proteins.
Collapse
|
40
|
Jiménez JB, Orea JM, Montero C, Ureña AG, Navas E, Slowing K, Gómez-Serranillos MP, Carretero E, De Martinis D. Resveratrol treatment controls microbial flora, prolongs shelf life, and preserves nutritional quality of fruit. J Agric Food Chem 2005; 53:1526-1530. [PMID: 15740035 DOI: 10.1021/jf048426a] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
Resveratrol is known as a grapevine secondary metabolite with fungicide activity. Its exogenous application on harvested grapes resulted in the reduction of microbial flora growth, and consequently, prolonged shelf life, without affecting the nutritional quality of the fruit. Resveratrol treatment also resulted in being effective on fruit that normally does not accumulate such metabolites as, for example, tomatoes, apples, avocado pears, and peppers. As a result, all treated fruits maintained their post-harvest quality and health longer than the untreated ones. This study demonstrates the potential use of resveratrol as a natural pesticide to reduce post-harvest fungi development on a broad spectrum of fruit types.
Collapse
Affiliation(s)
- Jorge Bernardo Jiménez
- Unidad de Láseres y Haces Moleculares, Instituto Pluridisciplinar, Universidad Complutense de Madrid, PC Juan XXIII, 1. 28040-Madrid, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Oñate JC, Sanhueza P, Alarcón E, López R, Montero C, Mandiola E. Presencia del Apéndice Fibroso Hepático: Estudio de Correlaciones Bioantropológicas y su Estructura. INT J MORPHOL 2005. [DOI: 10.4067/s0717-95022005000300004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
42
|
Abstract
OBJECTIVES To review the research on the effects and indications of eccentric muscular contraction in the athlete. METHODS We searched the Medline database using the key words eccentric and negative work for reports of eccentric muscular contraction published from 1993 to 2004. RESULTS The physiologic features of eccentric contraction remain unknown but significantly differ from concentric contraction. Eccentric contraction has a specific effect: during sports practice, it permits the muscular and tendinous complex to support strain and strengthens the muscular action of articular stabilization. But eccentric contraction produces injuries: delayed-onset muscle soreness, and muscle rupture and tendinous injuries such as luxation, rupture, and tendinitis. CONCLUSION Treatment and prevention must have controlled protocols. In therapy, eccentric contraction must be realized at progressive speeds and resistances. Prevention of tendinous injury necessitates quantifying eccentric activity during training.
Collapse
Affiliation(s)
- P Middleton
- Clinique de médecine physique et réadaptation Napoléon, allées de Christus, 40990 Saint-Paul-Lès-Dax, France
| | | |
Collapse
|
43
|
Morato M, Gasmi K, Montero C, González Ureña A. Molecular beam electric resonance without A and B fields: NO versus (NO)2 depletion spectra. Chem Phys Lett 2004. [DOI: 10.1016/j.cplett.2004.04.123] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
44
|
Montero C, Deben G, de la Torre M, Álvarez A, Verea H. Síndrome de Pancoast e infiltración tumoral endobronquial como primera manifestación de un linfoma de Hodgkin. Arch Bronconeumol 2004. [DOI: 10.1157/13061440] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
45
|
Montero C, Deben G, de la Torre M, Alvarez A, Verea H. [Pancoast syndrome and endobronchial tumor infiltration as the first manifestation of Hodgkin lymphoma]. Arch Bronconeumol 2004; 40:287-9. [PMID: 15161597 DOI: 10.1016/s1579-2129(06)70101-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
The most common cause of Pancoast syndrome is bronchogenic carcinoma. Other less common causes are solid tumor metastases, other chest tumors, infections, and hematologic neoplasms. Pancoast syndrome due to lymphoma is very rare, and cases described in the literature are essentially associated with non-Hodgkin lymphomas. In a review of the literature we found a single case of Pancoast syndrome secondary to a Hodgkin lymphoma; however, the syndrome manifested during recurrence of disease in that patient. We report a case of nodular sclerosis Hodgkin lymphoma which first manifested clinically as Pancoast syndrome and which was initially diagnosed by bronchial biopsy.
Collapse
Affiliation(s)
- C Montero
- Servicio de Neumología, Hospital Universitario Juan Canalejo, A Coruña, Spain
| | | | | | | | | |
Collapse
|
46
|
Fernández de la Pradilla R, Buergo MV, Martínez MV, Montero C, Tortosa M, Viso A. Sulfur-Directed Synthesis of Enantiopure Hydroxy 2-Sulfinyl Butadienes. J Org Chem 2004; 69:1978-86. [PMID: 15058943 DOI: 10.1021/jo035750g] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The treatment of sulfinyl chlorohydrins with KO-t-Bu in THF generates epoxy vinyl sulfoxides that undergo an efficient base-induced rearrangement to generate enantiopure hydroxy 2-sulfinyl dienes. This novel process takes place with high chemo- and stereoselectivity. The chirality at sulfur effectively controls the geometry of the trisubstituted alkene.
Collapse
|
47
|
Mandiola E, del Sol M, Olave E, Alarcón E, Montero C, Sanhueza P, Oñate JC. ANÁLISIS BIOMÉTRICO ENTRE MEDICIONES BIOANTROPOLÓGICAS CEFÁLICAS Y LA ARTERIA BASILAR. INT J MORPHOL 2004. [DOI: 10.4067/s0717-95022004000200011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
48
|
Montero C, Deben G, de la Torre M, Álvarez A, Verea H. Síndrome de Pancoast e infiltración tumoral endobronquial como primera manifestación de un linfoma de Hodgkin. Arch Bronconeumol 2004. [DOI: 10.1016/s0300-2896(04)75522-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
49
|
Xaubet A, Ancochea J, Blanquer R, Montero C, Morell F, Rodríguez Becerra E, Sueiro A, Villena V. Diagnóstico y tratamiento de las enfermedades pulmonares intersticiales difusas. Arch Bronconeumol 2003. [DOI: 10.1157/13054364] [Citation(s) in RCA: 61] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
50
|
Fernández de la Pradilla R, Manzano P, Montero C, Priego J, Martínez-Ripoll M, Martínez-Cruz LA. Nucleophilic Epoxidation of α‘-Hydroxy Dienyl Sulfoxides. J Org Chem 2003; 68:7755-67. [PMID: 14510552 DOI: 10.1021/jo0349173] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
A novel route to enantiopure densely functionalized epoxy sulfinyl tetrahydrofurans, based on the unexpected and highly stereoselective remote nucleophilic epoxidation of hydroxy 1-sulfinyl butadienes with t-BuOOK, followed by ring closure and subsequent epoxidation of the resulting sulfinyl dihydrofurans, is described. Alternatively, the treatment of these dienes with m-CPBA followed by acid-catalyzed cyclization gives rise to related sulfonyl dihydrofurans in high yields but with low selectivity. The stereochemical outcome of the nucleophilic epoxidation of these substrates has also been studied.
Collapse
|